<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/263137</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Biophysics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Specific Eph Receptor-Cytoplasmic Effector Signaling Mediated by SAM-SAM Domain Interactions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yue</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shang</surname>
<given-names>Yuan</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4084-6679</contrib-id>
<name>
<surname>Li</surname>
<given-names>Jianchao</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Weidi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Gang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wan</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8250-2562</contrib-id>
<name>
<surname>Liu</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9404-0190</contrib-id>
<name>
<surname>Zhang</surname>
<given-names>Mingjie</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Shenzhen Key Laboratory for Neuronal Structural Biology, Biomedical Research Institute, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center</institution>, Shenzhen 518036, <country>China</country></aff>
<aff id="a2"><label>2</label><institution>Division of Life Science, State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology</institution>, Clear Water Bay, Kowloon, Hong Kong, <country>China</country>.</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Corresponding authors: Wei Liu (<email>liuwei@sphmc.org</email>) and Mingjie Zhang (<email>mzhang@ust.hk</email>)</corresp>
<fn id="n1" fn-type="present-address"><label>3</label><p>Present address: Center for Biomedical Informatics and Biostatistics &#x0026; Center for Innovation in Brain Science, The University of Arizona, 1657 East Helen Street, Tucson, AZ 85721</p></fn>
</author-notes>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>263137</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>09</day>
<month>2</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="263137.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>The Eph receptor tyrosine kinase (RTK) family is the largest subfamily of RTKs playing critical roles in many developmental processes such as tissue patterning, neurogenesis and neuronal circuit formation, angiogenesis, etc. How the 14 Eph proteins, via their highly similar cytoplasmic domains, can transmit diverse and sometimes opposite cellular signals upon engaging ephrins is a major unresolved question. Here we systematically investigated the bindings of each SAM domain of Eph receptors to the SAM domains from SHIP2 and Odin, and uncover a highly specific SAM-SAM interaction-mediated cytoplasmic Eph-effector binding pattern. Comparative X-ray crystallographic studies of several SAM-SAM heterodimer complexes, together with biochemical and cell biology experiments, not only revealed the exquisite specificity code governing Eph/effector interactions but also allowed us to identify SAMD5 as a new Eph binding partner. Finally, these Eph/effector SAM heterodimer structures can explain numerous Eph SAM mutations identified in patients suffering from cancers and other diseases.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Eph receptor</kwd>
<kwd>ephrin-Eph signaling</kwd>
<kwd>SHIP2</kwd>
<kwd>Odin</kwd>
<kwd>SAM domain</kwd>
<kwd>SAMD5</kwd>
</kwd-group>
<counts>
<page-count count="39"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The Eph (<underline>E</underline>rythropoietin <underline>P</underline>roducing <underline>H</underline>epatocyte) transmembrane receptor tyrosine kinase superfamily, with its first member identified exactly 30 years ago (<xref ref-type="bibr" rid="c17">Hirai, 1987</xref>), contains 14 members in mammals and is the largest among all receptor tyrosine kinase families (<xref ref-type="bibr" rid="c23">Lemmon and Schlessinger, 2010</xref>; <xref ref-type="bibr" rid="c28">Manning et al., 2002</xref>; <xref ref-type="bibr" rid="c35">Murai and Pasquale, 2003</xref>). Chiefly based on their engaging ephrin ligands, Eph receptors are classified into the EphA and EphB subfamilies, each with nine and five members in mammals, respectively (<xref ref-type="bibr" rid="c8">Committee, 1997</xref>; <xref ref-type="bibr" rid="c13">Gale et al., 1996</xref>; <xref ref-type="bibr" rid="c35">Murai and Pasquale, 2003</xref>). Owing to broad expressions in essentially all tissues and at every life stage, Ephrin-Eph signaling regulates many cellular processes both during development and in developed animals such as stem cell maintenance and differentiations, tissue morphogenesis, and tissue-tissue boundary formation (<xref ref-type="bibr" rid="c4">Batlle and Wilkinson, 2012</xref>; <xref ref-type="bibr" rid="c14">Genander and Frisen, 2010</xref>; <xref ref-type="bibr" rid="c18">Julich et al., 2009</xref>; <xref ref-type="bibr" rid="c30">McMillen and Holley, 2015</xref>; <xref ref-type="bibr" rid="c34">Munarini, 2002</xref>; <xref ref-type="bibr" rid="c38">Park et al., 2011</xref>; <xref ref-type="bibr" rid="c42">Poliakov et al., 2004</xref>). Not surprisingly, mutations of ephrins and Ephs are known to cause many forms of diseases including cancers and brain disorders (<xref ref-type="bibr" rid="c5">Boyd et al., 2014</xref>; <xref ref-type="bibr" rid="c6">Chen, 2008</xref>; <xref ref-type="bibr" rid="c15">Hahn et al., 2012</xref>; <xref ref-type="bibr" rid="c19">Kania and Klein, 2016</xref>; <xref ref-type="bibr" rid="c32">Merlos-Suarez and Batlle, 2008</xref>; Pasquale, 2008; <xref ref-type="bibr" rid="c53">Zhuang et al., 2012</xref>).</p>
<p>Ephrin ligand binding-mediated inter-cellular signaling is the classic mode of Eph receptor signaling (also known as ephrin-Eph &#x201C;forward&#x201D; signaling), which is responsible for the majority of cellular functions characterized for the ephrin-Eph signaling (<xref ref-type="bibr" rid="c41">Pitulescu and Adams, 2010</xref>; <xref ref-type="bibr" rid="c46">Taylor et al., 2017</xref>; <xref ref-type="bibr" rid="c50">Yokoyama, 2001</xref>). Presumably, the versatile forward ephrin-Eph signals are transmitted by the cytoplasmic portion of Eph receptors. However, the cytoplasmic portion of all 14 Eph receptors are highly similar, each containing a membrane-juxtaposing kinase domain, a protein- binding SAM domain immediately followed by a short carboxyl tail PDZ domain binding motif (PBM) (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The cytoplasmic portions of Eph receptors are often presumed to function similarly. However, multiple Eph receptors are typically coexpressed in one tissue. Paradoxically, it has been observed that two different Eph receptors on the same cell type can respond to a single ephrin ligand but elicit opposite cellular responses. For example, ephrin-A5 binds to EphA2 and EphA4 with similar affinity but induces cell adhesion or cell collapse, respectively (<xref ref-type="bibr" rid="c9">Cooper et al., 2008</xref>; <xref ref-type="bibr" rid="c51">Zhou et al., 2007</xref>). Therefore, the cytoplasmic domains of Eph receptors must be able to engage different intracellular effectors in response to ephrin ligands. How specific Eph receptor cytoplasmic domain-mediated signaling might occur has been a major unresolved question in the ephrin-Eph signaling.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Several EphA SAM domains specifically bind to SHIP2 SAM or Odin SAM.</title><p>(A) Schematic diagrams showing the domain organizations of EphA2, SHIP2 and Odin.</p>
<p>(B-C) Analytical gel-filtration chromatography (B) and ITC-based measurements (C) showing the interaction between EphA2 SAM and SHIP2 SAM.</p>
<p>(D) Summary of the dissociation constants between Eph SAMs and SHIP2/Odin SAMs. All binding affinities were derived from ITC-based assays.</p>
<p>(E-F) Analytical gel-filtration chromatography (E) and ITC-based measurements (F) of the binding of EphA2 SAM to Odin SAM.</p></caption>
<graphic xlink:href="263137_fig1.tif"/>
</fig>
<p>We reasoned that the SAM domain of each Eph receptor is likely to play a role in specifying their cytoplasmic effector engagements for the following two reasons. First, SAM domain is a well-known protein-protein interaction module (<xref ref-type="bibr" rid="c43">Qiao and Bowie, 2005</xref>), and the SAM domain of EphA2 is known to bind to SAM domain from SHIP2 (SH2 domain-containing Inositol 5&#x2019;-Phosphatase 2, aka INPPL1 for INositol Polyphosphate Phosphatase-Like protein 1) and Odin (aka Anks1a) (<xref ref-type="bibr" rid="c20">Kim et al., 2010</xref>; <xref ref-type="bibr" rid="c22">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="c24">Leone et al., 2009</xref>; <xref ref-type="bibr" rid="c31">Mercurio et al., 2012</xref>; <xref ref-type="bibr" rid="c52">Zhuang et al., 2007</xref>), though the binding properties of the SAM domains from other Eph receptors are largely unknown. Second, although the PBM sequences of Eph receptors are somewhat different, the short PBM-mediated target bindings are rather promiscuous (<xref ref-type="bibr" rid="c49">Ye and Zhang, 2013</xref>) and thus unlikely to be fully responsible for the very diverse Eph intracellular signaling events. In this study, we systematically characterized and compared the bindings of the SAM domain from every Eph receptor to the SAM domains from SHIP2 and Odin. This characterization revealed a highly specific Eph SAM and effector SAM binding pattern. We then elucidated the mechanistic basis governing such specific Eph SAM and effector SAM binding by solving several pairs of the SAM-SAM heterodimer complexes structures. Such comparative structural analysis, together with biochemical, bioinformatics and cell biology studies, revealed an exquisitely specific effector binding code mediated by the Eph SAM domains, which helps to answer the major question on the ephrin-Eph forward signaling specificity. Additionally, our study also provides mechanistic explanations to numerous disease- causing mutations identified in the SAM domains of Eph receptors, and allows us to discover SAMD5 as a new intracellular effector of Eph receptors.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Interactions between Eph SAM domains and SHIP2 SAM or Odin SAM1</title>
<p>SHIP2 is a mammalian inositol polyphosphate 5-phosphatases and is the only member in the family that contains a C-terminal SAM domain (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). It has been reported that SHIP2 was a binding partner of EphA2 through SAM-SAM interaction (<xref ref-type="bibr" rid="c22">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="c24">Leone et al., 2009</xref>). We first confirmed this interaction. Both Eph SAM and SHIP2 SAM alone behaved as homogeneous monomers in solution as indicated by the analytical gel filtration analysis (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). While the 1:1 mixture of EphA2 SAM and SHIP2 SAM was eluted at a smaller volume than the individual protein, suggesting the formation of a hetero SAM-SAM complex (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). ITC (Isothermal Titration Calorimetry) experiment revealed that EphA2 SAM bound to SHIP2 SAM with a dissociation constant (Kd) of &#x007E;2.22 &#x03BC;M at a 1:1 stoichiometry (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). We then measured the binding affinities of SHIP2 SAM with the SAM domain from other members of Eph receptors by ITC. We found that only the SAM domains of EphA1/EphA2/EphA6 specifically bound to SHIP2 SAM, and the rest of Eph SAM domains displayed no detectable binding to SHIP2 SAM (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p>
<p>Odin was reported to be another binding partner of EphA2 (<xref ref-type="bibr" rid="c20">Kim et al., 2010</xref>; <xref ref-type="bibr" rid="c31">Mercurio et al., 2012</xref>), and the interaction had been implicated in affecting the stability of EphA2 by modulating its ubiquitination process (<xref ref-type="bibr" rid="c20">Kim et al., 2010</xref>). We also verified the interactions between Odin and Eph receptors SAM domains (<xref ref-type="fig" rid="fig1">Figure 1E&#x0026;F</xref>). The results showed that, similar to SHIP2 SAM, Odin SAM1 only selectively bound to the SAM domains from EphA1/EphA2/EphA6 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The quantitative and systematic binding results shown in <xref ref-type="fig" rid="fig1">Figure 1D</xref> indicated that the interactions between Eph SAMs and their downstream effectors were highly specific.</p>
</sec>
<sec id="s2b">
<title>Overall structures of the EphA2/SHIP2 and EphA6/Odin SAM-SAM complexes</title>
<p>To elucidate the molecular mechanism governing the specificity of the bindings of SHIP2 SAM and Odin SAM1 to Eph receptors, we determined the crystal structure of the SHIP2 SAM-EphA2 SAM complex and the Odin SAM1-EphA6 SAM complex at the 1.5 &#x00C2; and 1.3 &#x00C2; resolutions, respectively (<xref ref-type="table" rid="tbl1">Table 1</xref>). The crystals diffracting at very high resolutions of both complexes were facilitated by fusing the Eph SAM domain to the C-terminal tail of the SHIP2 SAM or Odin SAM1 with a flexible linker (14 residues &#x201C;SSGENLYFQSGSSG&#x201D; for the SHIP2 SAM-EphA2 SAM complex; 17 residues &#x201C;PSGSSGENLYFQSGSSG&#x201D; for the Odin SAM1-EphA6 SAM complex). The covalent linkage did not appear to affect the overall structure of the complexes, as the linkers in both complexes are sufficiently long and flexible (Figure S1).</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><p>Statistics of X-ray Crystallographic Data Collection and Model refinement</p></caption>
<graphic xlink:href="263137_tbl1.tif"/>
</table-wrap>
<p>The two complex structures adopt an essentially identical End-Helix/Mid-Loop binding mode, in which positively charged residues from the N-terminal end of &#x03B1;5 (End-Helix, EH) of EphA2/EphA6 bind to negatively charged residues from the loop connecting &#x03B1;2-&#x03B1;4 (Mid-Loop, ML) from SHIP2/Odin, forming the well-known tail-to- head SAM domain heterodimer (<xref ref-type="fig" rid="fig2">Figure 2A-E</xref>) (<xref ref-type="bibr" rid="c43">Qiao and Bowie, 2005</xref>). The structures determined in this study were also consistent with an earlier NMR-derived EphA2 SAM/SHIP2 SAM heterodimer (<xref ref-type="bibr" rid="c22">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="c24">Leone et al., 2009</xref>). However, it should be noticed that some of the critical features mediating the specific SAM-SAM interaction revealed in our study were not revealed in the NMR structures (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="figS2">Figure S2</xref>), likely due to insufficient distance restraints of the NMR experiments. To avoid redundancy, we will not describe the detailed binding interactions of the two complexes here, except that we further validated some of such charge-charge interactions using site substitution approach (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). The structures of the complexes also revealed that the surfaces of the EphA2/EphA6 SAM Mid-Loop do not complement with the surfaces of the End-Helix of their own or with those of the SHIP2/Odin SAM domains (Figure S3), explaining that these four SAM domains neither form homo-oligomers nor polymerize into hetero-oligomers (<xref ref-type="bibr" rid="c21">Knight et al., 2011</xref>; <xref ref-type="bibr" rid="c43">Qiao and Bowie, 2005</xref>; <xref ref-type="bibr" rid="c45">Stapleton et al., 1999</xref>; <xref ref-type="bibr" rid="c47">Thanos et al., 1999</xref>). A noticeable feature in both complexes is that the backbone methylene of a Gly residue at the beginning of &#x03B1;5 from Eph SAM (Gly954<sup>A2</sup>/Gly1104<sup>A6</sup>) is in close contact with an aromatic residue from SHIP2/Odin SAM (Trp1221<sup>SHIP2</sup>/Phe738<sup>Odin</sup>) (<xref ref-type="fig" rid="fig2">Figure 2B&#x0026;D</xref> and <xref ref-type="fig" rid="figS4">Figure S4</xref>). As such, replacing Gly at the beginning of &#x03B1;5 of Eph SAM with any other amino acid residues will introduce steric hindrance in preventing their binding to SHIP2/Odin SAM. It is further noted that Gly is highly preferred at the beginning of &#x03B1;5 among Eph SAM domains (12 out of the 14 members are Gly; see Figure S5A).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>The detailed interactions governing the formation of the EphA2 SAM-SHIP2 SAM and the EphA6 SAM-Odin SAM1 complexes.</title><p>(A&#x0026;C) Ribbon representations of the EphA2 SAM-SHIP2 SAM (A) and the EphA6 SAM-Odin SAM1 (C) complex structures.</p>
<p>(B&#x0026;D) Details of the interfaces in the EphA2 SAM-SHIP2 SAM (B) and EphA6 SAM-Odin SAM1</p>
<p>(D) complexes. Key residues are shown with the stick model. Salt bridges and hydrogen bonds are indicated with dashed lines. The Gly-aromatic residue pairs (Gly954<sup>A2</sup>/Gly1104<sup>A6</sup> and Trp1221<sup>SHIP2</sup>/Phe738<sup>Odin</sup>) are indicated with red dashed circles.</p>
<p>(E) Superposition of two the EphA2 SAM-SHIP2 SAM and the EphA6 SAM-Odin SAM1 complex structures with the critical R958/F1226 and R1108/F743 pairs highlighted with the stick model. (F-G) Details of the planar cation-&#x03C0; interaction between EphA2 R958 and SHIP2 F1226 (F), and EphA6 R1108 and Odin F743 (G). Note the planar alignment of the &#x03C0; electrons of the Arg sidechain and the neighboring peptide backbones in both structures.</p>
<p>(H) Summary of the ITC-derived results showing that the mutations of the critical residues in the SAM domain interface can dramatically affect the bindings of EphA SAMs to the SAM domains from SHIP2 or Odin.</p>
<p>(I) The Bindings of EphA2 SAM or its various mutants to the full-length SHIP2 by the GST pulldown assay.</p>
<p>(J) The bindings of SHIP2 SAM or its F1226L-mutant to the full-length WT GFP-EphA2 analysed by the GST pull-down assay.</p>
<p>(K) GST pull-down assay showing that the K857R mutant of EphA5 SAM gained its binding to SHIP2.</p></caption>
<graphic xlink:href="263137_fig2.tif"/>
</fig>
<p>The very high-resolution crystal structures of the two complexes also allowed us to identify a unique interaction feature that is critical for the exquisite specific interaction between the EphA2/A6 SAM domain and SHIP2/Odin SAM domains. Taking the EphA2/SHIP2 complex as the example, a special cation-&#x03C0; interaction between the Arg958<sup>A2</sup> and Phe1226<sup>SHIP2</sup> was uncovered by the high-resolution crystal structure (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). The guanidinium group of Arg958<sup>A2</sup> forms hydrogen bond network with Asp1222<sup>SHIP2</sup> and His955<sup>A2</sup> on one side and with the backbone carbonyl oxygen of Ile917<sup>A2</sup>. As such the guanidinium plane of Arg958<sup>A2</sup> (and its delocalized &#x03C0;- system) is in the same plane with the &#x03C0;-system of the planer peptide bond between Ile917<sup>A2</sup> and Lys918<sup>A2</sup>, forming energetically favorable &#x03C0;-&#x03C0; stacking with the benzene ring of Phe1226<sup>SHIP2</sup> (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) (<xref ref-type="bibr" rid="c27">Ma and Dougherty, 1997</xref>). The exactly same interaction pattern occurs for the EphA6/Odin complex (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). It is predicted that alteration of any of the interactions in the above described &#x03C0;-&#x03C0; stacking will perturb the binding of EphA2/6 to SHIP2 or Odin. The most subtle substitution of Arg is probably by the positively charged Lys. Consistent with the binding pattern, the corresponding residue of Arg958 in EphA2 is also found in EphA1 and A6, which could interact with SHIP2 and Odin. Whereas the rest of Eph SAMs contain a Lys in this position except EphA10, which is an Ala (Figure S5). Based on the structures shown in <xref ref-type="fig" rid="fig2">Figure 2F</xref>, replacing Arg958<sup>A2</sup> with Lys would eliminate the planar &#x03C0;-system formed by Arg958<sup>A2</sup> and the Ile917<sup>A2</sup>-Lys918<sup>A2</sup> peptide bond and thus seriously weaken the binding, even though the positive charge at the site is retained. Totally consistent with this structural analysis, substitution of Arg958<sup>A2</sup> with Lys completely eliminated the bindings of EphA2 SAM to SHIP2 SAM or Odin SAM (<xref ref-type="fig" rid="fig2">Figure 2H&#x0026;I</xref>). Correspondingly, substitution of Phe1226 of SHIP2 SAM with non-aromatic hydrophobic residues (e.g. Leu or Ala) also totally eliminated the binding between SHIP2 SAM and EphA2 SAM (<xref ref-type="fig" rid="fig2">Figure 2H&#x0026;J</xref>). Additionally, replacing Asp1222 in SHIP2 SAM with Ala also eliminated the binding between SHIP2 and EphA2, highlighting the importance of the hydrogen bond between Asp1222<sup>SHIP2</sup> and Arg958<sup>A2</sup> in stabilizing the guanidinium group of Arg958 (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). We mined COSMIC cancer somatic mutation database (<xref ref-type="bibr" rid="c11">Forbes et al., 2017</xref>; <ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cosmic">http://cancer.sanger.ac.uk/cosmic</ext-link>) and found that an Arg957 (corresponding to mouse Arg958) to Cys somatic mutation of EphA2 has been detected in ovary carcinoma patients. As expected, substitution of Arg with Cys also completely eliminated EphA2 SAM&#x2019;s binding to the SHIP2 or Odin (<xref ref-type="fig" rid="fig2">Figure 2H&#x0026;I</xref>).</p>
<p>The above structural and biochemical analysis highlights the critical role and the exquisite selectivity of Arg958 in EphA2 (or the corresponding Arg in EphA1/EphA6) in terms of bindings to the effectors such as SHIP2 and Odin. We pushed this concept further by testing whether we might be able to convert a non SHIP2/Odin binding Eph SAM domain into a binding one by simply substituting the Lys at the position corresponding Arg958<sup>A2</sup> to Arg (i.e. a single residue &#x201C;gain-of-function&#x201D; mutation). We chose EphA5 SAM domain to test this hypothesis, as it shares &#x007E;50&#x0025; sequence identity to EphA2 SAM but has no or minimal binding to SHIP2 or Odin (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Satisfyingly, substituting Lys857 (corresponding Arg958<sup>A2</sup>) with Arg converted EphA5 SAM into a SHIP2 binding SAM domain, though the binding was still relatively weak. The same substitution also enhanced EphA5 SAM&#x2019;s binding to Odin SAM1 by more than 100-fold (<xref ref-type="fig" rid="fig2">Figure 2H</xref>, <italic>bottom).</italic> Taken together, the above structural and biochemical analysis highlighted that the SAM-SAM domain interactions between Eph receptors and their cytoplasmic effectors are highly specific.</p>
</sec>
<sec id="s2c">
<title>Specific SAM domain-mediated effector binding is required for ligand-induced cell repulsion function of EphA2</title>
<p>We next tested the cellular function of the specific SAM domain-mediated effector association of the EphA2. DU145 cells, which have a low expression level of endogenous EphA2 receptors, were used to study its ligand-induced inhibition of cell spreading (<xref ref-type="bibr" rid="c2">Barquilla et al., 2016</xref>; <xref ref-type="bibr" rid="c22">Lee et al., 2012</xref>; <xref ref-type="bibr" rid="c33">Miao et al., 2000</xref>; <xref ref-type="bibr" rid="c44">Shi et al., 2017</xref>). To focus our studies on the forward signal pathway of EphA2, we chose to engage the EphA2 receptor by adding soluble ephrinA1-Fc chimera to the cell culture media. To minimize potential trans signaling from neighboring cells, all experiments were performed in low-density cultures (at about 30&#x0025; confluency or below). Cells were infected with the lenti-virus containing the 3&#x002A;Flag-tagged EphA2 FL WT, EphA2- R958K, EphA2 with the SAM domain deleted (EphA2 delSAM), and EphA2 with its SAM substituted by EphA5 SAM (EphA2-SAMA5 chimera). Cells infected with the 3&#x002A;Flag-tagged GFP were the negative controls. As expected and consistent with the previous reports (<xref ref-type="bibr" rid="c2">Barquilla et al., 2016</xref>; <xref ref-type="bibr" rid="c44">Shi et al., 2017</xref>), in response to ephrinA1-Fc stimulation, cells expressing the wild-type full-length EphA2 receptor dramatically retracted and became rounded, whereas the negative control cells did not respond to ephrinA1 (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and quantified in <xref ref-type="fig" rid="fig3">Figure 3B</xref>). Using this specific EphA2-mediated cell rounding assay, the repulsion phenotype of the cells expressing EphA2 delSAM, EphA2 R958K or EphA2-SAMA5 chimera were evaluated. None of them displayed ephrinA1-induced cell rounding (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3">3B</xref>), indicating that the highly specific EphA2 SAM domain-mediated effector association is required for the cell spreading function of EphA2.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Impacts of the mutations in SAM domain of EphA2 on the RTK&#x2019;s function in cell spreading.</title><p>(A) Selected images showing the morphologies of DU145 cells expressing the wild-type or various mutants of EphA2 before and after ephrin A1-Fc treated. Cells were stained for F-actin with fluorescent phallodin (red), and nuclei were labelled with DAPI (blue).</p>
<p>(B) Quantification of the cell areas of DU145 cells expressing various constructs. Data represents the mean &#x00B1; SEM from four independent experiments with each experiment of at least 400 cells. (&#x002A;&#x002A;, P &#x003C; 0.01 by one-way ANOVA with Tukey&#x2019;s multiple comparison test)</p></caption>
<graphic xlink:href="263137_fig3.tif"/>
</fig>
</sec>
<sec id="s2d">
<title>SAMD5 as a new effector of Eph SAM</title>
<p>The above crystal structures of EphA2-SHIP2 and EphA6-Odin revealed the importance of the negatively charged residues within the &#x03B1;2-&#x03B1;3 loop and at the beginning of the &#x03B1;4 helix of SAM domain in binding to Eph SAM (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig4">Figure 4A</xref>). We tried to look for new binding partners for Eph SAMs. By inspecting each of the 163 SAM domains in 127 mouse SAM domain containing proteins (SMART&#x2019;s nrdb database: <ext-link ext-link-type="uri" xlink:href="http://smart.embl-heidelberg.de/">http://smart.embl-heidelberg.de/</ext-link>), we found several potential candidates that may interact with Eph SAM. AIDA1, also named as Ankyrin repeat and sterile alpha motif domain-containing protein 1B (Anks1b), is a paralog of Odin (Anks1a) and thus its SAM1 domain is expected to bind to EphA2/A6 SAM with the same mode and specificity as Odin SAM1 does. Another promising candidate is SAMD5, whose SAM domain is similar to SHIP2 SAM (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and highly expressed in breast cancer cells and mainly cytoplasmic (<xref ref-type="bibr" rid="c26">Lo et al., 2015</xref>).</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Characterization of SAMD5 as a new effector of Eph SAM</title><p>(A) Sequence alignment of the SAM domains of SHIP2, Odin and two potential interaction partners (AIDA1 and SAMD5).</p>
<p>(B&#x0026;C) ITC (B) and analytical gel-filtration chromatography (C) showing that SAMD5 binds to EphA5 SAM.</p>
<p>(D) ITC-derived dissociation constants showing that SAM domains from EphA5-8 and EphB1-4 bind to SAMD5 SAM.</p></caption>
<graphic xlink:href="263137_fig4.tif"/>
</fig>
<p>We purified SAMD5 SAM and measured its binding to the SAM domain of every Eph receptor. Indeed, SAMD5 SAM was found to be a strong binder of Eph SAM domains such as EphA5 and others (<xref ref-type="fig" rid="fig4">Figure 4B-D</xref>). Surprisingly, although the amino acid sequence of SAMD5 SAM can be aligned well (the key binding residues in particular) with the SAM domain sequences of SHIP2 and Odin (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <italic>top</italic>), SAMD5 bound to EphA5-8 and EphB1-4 SAM domains with strong affinities but only weakly to EphA1/2 SAM domains (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). This biochemical data further substantiated that the SAM domains of Eph receptors can provide diverse binding specificities to their effectors.</p>
</sec>
<sec id="s2e">
<title>EphA5/SAMD5 SAM-SAM complex structure reveals the binding specificity</title>
<p>To delineate the mechanism governing the Eph/SAMD5 interaction, we solved the EphA5/SAMD5 SAM-SAM complex crystal structure at the resolution of 1.9 &#x00C2; (<xref ref-type="table" rid="tbl1">Table 1</xref>). Similar to that of EphA2/SHIP2 or EphA6/Odin, EphA5 SAM also uses its End- Helix to interact with the Mid-Loop SAMD5 SAM (<xref ref-type="fig" rid="fig5">Figure 5A&#x0026;B</xref>). However, their detailed binding mechanisms are quite different. The most prominent difference is that the EphA5/SAMD5 SAM-SAM does not contain the &#x03C0;-&#x03C0; stacking observed in the EphA2/SHIP2 and EphA6/Odin complexes (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Instead, the EphA5/SAMD5 SAM-SAM is essentially completely mediated by charge-charge and hydrogen bonding interactions (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Perturbation of these interactions invariably weakened the interaction (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Similar to what we observed in the EphA2/SHIP2 and EphA6/Odin structures, Gly853<sup>A5</sup> at the beginning of &#x03B1;5 in EphA5 SAM is also critical for its binding to SAMD5 SAM. The backbone amine of Gly853<sup>A5</sup> forms a strong hydrogen bond with Tyr27<sup>SAMD5</sup> sidechain hydroxyl group (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). This hydrogen bond brings the &#x03B1;2-&#x03B1;3 loop of SAMD5 very close to &#x03B1;5 of EphA5 (Figure S4C), and the site has no room to accommodate any residues with side chains, further highlighting the importance of a Gly at this position in the Eph SAM domains (Figure S5A). To our surprise, substitution of Tyr27<sup>SAMD5</sup> with Phe completely eliminated SAMD5&#x2019;s binding to EphA5 (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), indicating the critical role of the Gly853<sup>A5</sup>-Tyr27<sup>SAMD5</sup> hydrogen binding in addition to their steric role.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>The detailed interaction between EphA5 SAM and SAMD5 SAM</title><p>(A) Ribbon diagram showing the overall structure of the EphA5/SAMD5 complex.</p>
<p>(B) Superposition of the EphA5/SAMD5 and EphA2/SHIP2 complex structures by aligning EphA5 and EphA2 together. SAMD5 and SHIP2 use different surfaces to interact with the same site on the SAM domains from EphA5 and EphA2.</p>
<p>(C) Stereo view of the detailed interaction of the EphA5/SAMD5 complex. Key residues are shown with the stick model. Salt bridges and hydrogen bonds are indicated with dashed lines.</p>
<p>(D) Structure model showing that V852P mutation of EphA5 will introduce steric hindrance with Tyr27 and Asp40 from SAMD5 and thus impair the binding.</p>
<p>(E) ITC-derived dissociation constants showing mutations of critical residues weaken or abolish the binding between SAMD5 and EphA5, and a gain-of-function mutantion EphA2 SAM (P953A) with enhanced binding to SAMD5.</p></caption>
<graphic xlink:href="263137_fig5.tif"/>
</fig>
<p>Our crystal structure of the EphA5/SAMD5 complex can explain why SAMD5 does not bind to EphA1-4, EphA10, and EphB6. For the SAM domains from EphA3/EphA4/EphA10/EphB6, each has one or more of the key residues missing (e.g. EphA10 and EphB6 are missing Gly at the beginning of &#x03B1;5, and EphA3/4 SAMs are missing positively charged Lys at the end of &#x03B1;2 or in the middle of &#x03B1;5; Figure S5). For the EphA1/EphA2 SAM domains, although all the key residues are present, it is noticed that a Pro residue is at the position corresponding to Val852<sup>A5</sup> (Figure S5). The sidechain pyrrolidine ring of Pro would introduce steric hindrance with Asp40, and thus may perturb SAMD5 from binding to EphA1/EphA2 SAM domains (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), resulting in low affinities (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Supporting this analysis, replacing Val825 of EphA5 SAM with a Pro led to about 10-fold affinity decrease in its binding to SAMD5. Additionally, substitution Pro953 in EphA2 with a smaller residue Ala increased its SAMDs SAM binding by more than 10 fold (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Finally, EphA6 SAM could bind to both SAMD5 and SHIP2/Odin SAM domains (<xref ref-type="fig" rid="fig1">Figure 1D</xref>&#x0026;<xref ref-type="fig" rid="fig4">4D</xref>), since it satisfies the binding criteria of both types.</p>
</sec>
<sec id="s2f">
<title>Disease mutations of Eph SAM domains</title>
<p>Eph receptors mediate cell-cell contact signaling and are vital for cell adhesion and migration (<xref ref-type="bibr" rid="c19">Kania and Klein, 2016</xref>). It is not surprising that mutations of Eph receptors can cause various human diseases including cancers (<xref ref-type="bibr" rid="c3">Barquilla and Pasquale, 2015</xref>; <xref ref-type="bibr" rid="c5">Boyd et al., 2014</xref>; <xref ref-type="bibr" rid="c12">Gaitanos et al., 2015</xref>; <xref ref-type="bibr" rid="c14">Genander and Frisen, 2010</xref>; <xref ref-type="bibr" rid="c19">Kania and Klein, 2016</xref>; <xref ref-type="bibr" rid="c39">Pasquale, 2005</xref>, 2008, <xref ref-type="bibr" rid="c40">2010</xref>). We surveyed the COSMIC cancer somatic mutation database (<xref ref-type="bibr" rid="c11">Forbes et al., 2017</xref>; <ext-link ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cosmic">http://cancer.sanger.ac.uk/cosmic</ext-link>) and found that numerous mutations occur in almost every subtype of Eph genes except for EphB6. A significant number of these mutations fell into the SAM domain regions (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). The biochemical and structural information provided in this study allowed us to test the impact of these mutations found in cancer patients in terms of binding to the cytoplasmic effectors including SHIP2 and SAMD5. For the practical workload reason, we chose to investigate the mutation sites that are at the positions critical for the SAM/SAM interactions analyzed in our structural studies shown in <xref ref-type="fig" rid="fig2">Figure. 2</xref>&#x0026;<xref ref-type="fig" rid="fig5">5</xref>, and are shaded in orange in <xref ref-type="fig" rid="fig6">Figure 6A</xref>. We purified each of these mutant SAM domains of Eph proteins, and measured their individual bindings to SHIP2 SAM or SAMD5 SAM by ITC-based assays. The results are summarized in <xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6">C</xref>. As expected, EphA1 R966C, EphA2 R957C, and EphA6 R1014Q mutations (the cation-&#x03C0; forming Arg at &#x03B1;5 helix) totally abolished their binding to SHIP2 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Similar deleterious effect can also be seen in EphA1 &#x03B1;1-&#x03B1;2 loop mutation R926G (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). EphA5 G1014S, EphA7 G972V, and EphB3 G974D mutations disrupted their binding to SAMD5 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), further supporting our structural finding that the sidechain-less Gly at the beginning of &#x03B1;5 is critical (Figure S4). Mutations on other critical sites such as EphA5 K1018M, EphA6 R1014Q, EphA8 R943H, and EphB1 K926M, A961T all weakened or even disrupted their binding to SAMD5 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Taken together, the above analysis of the impact of the Eph SAM mutations found in cancer patients illustrated the tremendous values of the structural and biochemical studies of Eph SAM- mediated target interactions presented in the current study.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>Disease mutations of Eph SAM domains</title><p>(A) Sequences alignments of Eph SAMs. The secondary structure elements are labeled according to the EphA2 SAM structure. Residues that are identical and highly similar are shown in red and green, respectively. The residues critical in the SAM-SAM interactions are shaded in orange. Mutations within the SAM domain of all Eph receptors found in cancer patients are indicated in grey or magenta. The residues indicated in magenta were experimentally testedand shown in B&#x0026;C.</p>
<p>(B) Summary of the impacts of selected mutations of EphA1, A2, A6 identified in cancer patients (see panel A) on the SHIP2 binding.</p>
<p>(C) Summary the impacts of selected mutations of EphA5, A6, A7, A8 and EphB1, B2, B3 identified in cancer patients (see panel A) on the SAMD5 binding.</p></caption>
<graphic xlink:href="263137_fig6.tif"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Since the discovery of the Eph receptors three decades ago, numerous efforts have been invested in elucidating ligand-induced signaling mechanisms of this classical family of RTKs in many biological processes. However, in contrast to the explosive amount of information on the functions uncovered, our understandings of the forward signaling mechanisms of the receptors are relatively poor. It is particularly unclear how Eph receptors may engage their specific cytoplasmic effectors to transmit biological signals using their highly similar cytoplasmic domains. At present, very little knowledge is available on what downstream targets of Eph receptors are and whether each Eph receptor engages different cytoplasmic effectors upon ligand binding, and this has seriously hampered our understanding on the action mechanisms of this family of RTKs in both physiological and patho-physiological conditions.</p>
<p>In this study, we performed systematic biochemical and structural studies of the bindings of three SAM domains, two from previously identified Eph binding proteins (SHIP2 and Odin) and one from a new Eph binding protein discovered in this study (SAMD5), to the SAM domains from every Eph receptor. Our study reveals that the Eph SAM domains have exquisitely specific target SAM domain binding properties, although their overall SAM-SAM heterodimer formation modes are very similar. This result provides a partial answer in rationalizing diverse functions of Eph receptors that can be induced by the same or similar ephrin ligand(s). It is anticipated that there exist additional SAM domain containing proteins capable of binding to Eph receptors. Since there are 110 SAM domain-containing proteins in addition to the 14 Eph receptors and three Eph binding proteins studied here, one approach to identify new Eph SAM binding proteins is to survey bindings of all 14 Eph SAM domains to the rest of the SAM domains in the human proteome using purified recombinant proteins by protein array-based methods.</p>
<p>We demonstrated that, unlike many other previously characterized polymer forming SAM domains, all Eph SAM domain adopts stable monomers in solution (<xref ref-type="bibr" rid="c16">Harada et al., 2008</xref>; <xref ref-type="bibr" rid="c21">Knight et al., 2011</xref>; <xref ref-type="bibr" rid="c45">Stapleton et al., 1999</xref>; <xref ref-type="bibr" rid="c47">Thanos et al., 1999</xref>; <xref ref-type="bibr" rid="c48">Wang et al., 2016</xref>). The structures solved in this study revealed that the SAM domains from EphA2, EphA5, and EphA6 all bind to its effector SAM domain using their respective End-Helix. It is noticed that every Eph SAM domain also contains an extremely conserved Mid-Loop (see EphA2/EphA5/EphA6 SAM sequence alignments in Figure S5B-D for an example). It is compelling to speculate that at least some Eph SAM domains may also use their Mid-Loops to bind to the End-Helix of their effector SAM domains. This hypothesis is further supported by the observation that many residues in the Mid-Loop regions of Eph SAM domains are found to be mutated in cancer patients (<xref ref-type="fig" rid="fig6">Figure 6A</xref>).</p>
<p>The structures of Eph SAM domains in complex with the SAM domains of several different effectors presented in this study are very useful in interpreting numerous mutations/variants found in the Eph SAM domains in patients with different diseases (e.g. cancers analyzed in <xref ref-type="fig" rid="fig6">Figure 6</xref>). It is expected that not all mutations occur in the SAM domains will alter functions of Eph receptors. The structures of the SAM-SAM complexes presented in this work, coupled with amino acid sequence-based analysis, readily predict the following three categories of mutations that will likely alter functions of Eph receptors via changing their SAM domain structures and effector binding. First, mutations of residues in the folding core or residues playing other critical structural roles (e.g. residues highlighted in red in <xref ref-type="fig" rid="fig6">Figure 6A</xref>) may impair the overall structure and thus effector binding of Eph SAM domains. We tested a few of such mutations (e.g. EphA2 W913C and D944N), and found that these SAM mutants invariably expressed as inclusion bodies (data not shown). Second, mutations occur in the End-Helix region of Eph SAM domains. This category of Eph SAM domain mutants often has defects or even total impairments in binding to their effectors (<xref ref-type="fig" rid="fig6">Figure 6B&#x0026;C</xref>), and thus are expected to have impair downstream signaling. Third, mutations occur in the Mid-Loop region of the Eph SAM domains may also impair their binding to effector SAM domain as we mentioned above, although this prediction will need to be verified. We propose that the Eph SAM mutations found in patients that fall into the above three categories will have higher chance to be disease-relevant mutations and thus are given higher priority to be investigated. Certainly, it cannot be ruled out that mutations of the Eph SAM domains that are outside the three categories may also impair functions of Eph receptors, perhaps via still unknown SAM domain-mediated target bindings.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Protein expression and purification</title>
<p>DNA encoding EphA2 SAM (NP_034269.2, residues 901-977), SHIP2 SAM (NP_034697.2, residues 1201-1257), Odin SAM1 (NP_852078.1, residues 712-776) and SAMD5 SAM (NP_796245.2, residues 1-66) were amplified from <italic>Mus musculus</italic> cDNA libraries as the template and individually cloned into a modified pET vector (<xref ref-type="bibr" rid="c25">Liu et al., 2011</xref>). All mutants were created using the standard two-step PCR methods. The fusion constructs of SHIP2 SAM/EphA2 SAM and Odin SAM1/EphA6 SAM each contained a TEV protease recognition site &#x201C;ENLYFQ&#x201D; flanked by several Gly-Ser repeats as the flexible linkers.</p>
<p>Recombinant proteins with N-terminal His6-tag were expressed <italic>E.coli</italic> BL21 (DE3) strain. Expressed proteins were purified by the Ni<sup>2</sup>&#x002B;-NTA Sepharose&#x2122; 6 Fast Flow beads (GE Healthcare) affinity chromatography followed by a Superdex-200 prep grade size-exclusion chromatography (GE Healthcare) in a buffer containing 50 mM Tris, pH 7.5, 100 mM NaCl, 1 mM DTT, and 1 mM EDTA. The N-terminal His-tag of each protein was cleaved by 3C protease and removed by another step of size-exclusion chromatography.</p>
</sec>
<sec id="s4b">
<title>Analytical gel-filtration Chromatography</title>
<p>Analytical gel-filtration chromatography was performed on an AKTA system (GE Healthcare) using the Superose 12 10/300 GL column. Protein samples (each with 100 &#x03BC;L at 50 &#x03BC;M) were injected into the column pre-equilibrated with a buffer containing 50 mM Tris, pH 7.5, 100 mM NaCl, 1 mM DTT, and 1 mM EDTA.</p>
</sec>
<sec id="s4c">
<title>Isothermal titration calorimetry assay</title>
<p>Isothermal titration calorimetry experiments were carried out on the MicroCal ITC200 calorimeter (Malvern) at 25 &#x00B0;C. The concentration of the injected samples in the syringe was 500 &#x03BC;M, and the concentration of the samples in the cell was fixed at 50 &#x03BC;M. The sample in the syringe was sequentially injected into the sample cell with a time interval of 150 sec (0.5 &#x03BC;L for the first injection and 2 &#x03BC;L each for the following 19 injections). The titration data were analyzed by the Origin 7.0 software and fitted with the one-site binding model.</p>
</sec>
<sec id="s4d">
<title>Protein Crystallography</title>
<p>The SHIP2 SAM-EphA2 SAM fusion protein (with a 14-residue linker &#x201C;SSGENLYFQSGSSG&#x201D;), the Odin SAM-EphA6 SAM fusion protein (with a 17- residue linker &#x201C;PSGSSGENLYFQSGSSG&#x201D;), and a 1:1 mixture of SAMD5 SAM and EphA5 SAM were concentrated to &#x007E;10-20 mg/mL for crystallization. Crystals were obtained at 16 &#x00B0;C by the sitting-drop vapor diffusion against 80 &#x03BC;&#x0395; well solution using 48-well format crystallization plates. SHIP2 SAM-EphA2 SAM complex crystals were grown in a buffer containing 0.2 M Succinic acid pH 7.0, 20&#x0025; w/v Polyethylene glycol 3,350. Odin SAM1-EphA6 complex crystals were grown in a buffer containing 0.1 M HEPES sodium pH 7.5, 1.5 M lithium sulfate monohydrate. SAMD5 SAM-EphA5 SAM complex crystals were grown in a buffer containing 0.2 M ammonium acetate, 0.1 M BIS-TRIS pH 5.5, 25&#x0025; w/v Polyethylene glycol 3,350. Crystals were soaked in the crystallization solution containing additional 5&#x0025; (for SHIP2/EphA2 and SAMD5/EphA5) or 20&#x0025; (for Odin/EphA6) v/v glycerol for cryo-protection. Diffraction data were collected at the Shanghai Synchrotron Radiation Facility BL17U1 at 100 K. Data were processed and scaled using HKL2000 (<xref ref-type="bibr" rid="c37">Otwinowski and Minor, 1997</xref>).</p>
<p>Structures were all solved by molecular replacement with the EphA2 SAM domain (PDB: 3KKA) and the SHIP2 SAM domain (PDB: 2K4P) or the Odin first SAM domain (PDB: 2LMR) structures as the searching models using PHASER (<xref ref-type="bibr" rid="c29">Mccoy et al., 2007</xref>). Further manual model buildings and refinements were completed iteratively using Coot (<xref ref-type="bibr" rid="c10">Emsley et al., 2010</xref>) and PHENIX (<xref ref-type="bibr" rid="c1">Adams et al., 2010</xref>) or Refmac5 (<xref ref-type="bibr" rid="c36">Murshudov et al., 2011</xref>). The final models were validated by MolProbity (<xref ref-type="bibr" rid="c7">Chen et al., 2010</xref>). The final refinement statistics are summarized in <xref ref-type="table" rid="tbl1">Table 1</xref>. The structure figures were prepared by PyMOL (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org">http://www.pymol.org</ext-link>).</p>
</sec>
<sec id="s4e">
<title>GST Pulldown Assays</title>
<p>GST-tagged EphA2, EphA5, SHIP2, SAMD5 SAM domains and their mutant proteins or GST alone were incubated with HEK293T cell lysates expressing the GFP- tagged target proteins for 1 h at 4 &#x00B0;C. The mixture was then loaded onto 20 &#x03BC;L Glutathione Sepharose 4B beads (GE Healthcare) in PBS buffer for 0.5 h at 4&#x00B0;C. After washing twice, the proteins captured by the beads were eluted by boiling with SDS- PAGE loading buffer, resolved by SDS-PAGE and detected by an anti-GFP antibody using western blotting.</p>
</sec>
<sec id="s4f">
<title>DU145 Cell Spreading Assay</title>
<p>The full-length wild type EphA2, EphA2-R958K, EphA2 delSAM and EphA2- SAMa5 chimera, each with a C-terminal Flag tag, were individually cloned into the pLVX plasmid for commercial viral packaging (Shanghai Taitool Bioscience Co. Ltd). The lenti-viruses were used to infect DU145 cells and selected with 1 &#x03BC;g/mL puromycin for ten days and the expression levels of proteins were verified by immunoblotting.</p>
<p>Cells were preserved to passage into a chamber (ibid &#x03BC;-Slide VI<sup>04</sup>, Germany), starved for 4h in serum-free medium, and then stimulated with ephrinA1-Fc (R&#x0026;D Systems, 1 &#x03BC;g/mL in PBS) for 30 minutes at 37 C. The cells were then fixed for 15 min with 4&#x0025; paraformaldehyde in PBS and stained with rhodamine-conjugated phalloidin for 30 min. Cell morphologies were analyzed with a Zeiss Confocal microscopy (LM710) equipped with a digital camera with a 20&#x002A; objective lens. The cell areas were measured using the ImageJ software (<ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link>). Oneway ANOVA with Tukey&#x2019;s multiple comparison test was used to compare cell areas among different experimental groups, and presented with the GraphPad Prism software.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank the Shanghai Synchrotron Radiation Facility (SSRF) BL17U1 and BL19U1 for X-ray beam time. This work was supported by grants from the Minister of Science and Technology of China (2014CB910204), National Key R&#x0026;D Program of China (2016YFA0501903), Natural Science Foundation of Guangdong Province (2016A030312016), Shenzhen Basic Research Grant (JCYJ20160229153100269) and Asia Fund for Cancer Research to M.Z., and grants from the National Natural Science Foundation of China (No. 31670765) and Shenzhen Basic Research Grants (JCYJ20160427185712266 and JCYJ20170411090807530) to W.L. M.Z. is a Kerry Holdings Professor in Science and a Senior Fellow of IAS at HKUST.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Adams</surname>, <given-names>P.D.</given-names></string-name>, <string-name><surname>Afonine</surname>, <given-names>P.V.</given-names></string-name>, <string-name><surname>Bunkoczi</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>V.B.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>I.W.</given-names></string-name>, <string-name><surname>Echols</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Headd</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Hung</surname>, <given-names>L.W.</given-names></string-name>, <string-name><surname>Kapral</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Grosse-Kunstleve</surname>, <given-names>R.W.</given-names></string-name>, <string-name><surname>McCoy</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Moriarty</surname>, <given-names>N.W.</given-names></string-name>, <string-name><surname>Oeffner</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Read</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Terwilliger</surname>, <given-names>T.C.</given-names></string-name>, and <string-name><surname>Zwart</surname>, <given-names>P.H.</given-names></string-name> (<year>2010</year>). <article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title>. <source>Acta Crystallogr. D Biol. Crystallogr</source>. <volume>66</volume>, <fpage>213</fpage>&#x2013;<lpage>221</lpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Barquilla</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lamberto</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Noberini</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Heynen-Genel</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Brill</surname>, <given-names>L.M.</given-names></string-name>, and <string-name><surname>Pasquale</surname>, <given-names>E.B.</given-names></string-name> (<year>2016</year>). <article-title>Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation</article-title>. <source>Mol. Biol. Cell</source> <volume>27</volume>, <fpage>2757</fpage>&#x2013;<lpage>2770</lpage>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Barquilla</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Pasquale</surname>, <given-names>E.B.</given-names></string-name> (<year>2015</year>). <article-title>Eph receptors and ephrins: therapeutic opportunities</article-title>. <source>Annu. Rev. Pharmacol. Toxicol</source>. <volume>55</volume>, <fpage>465</fpage>&#x2013;<lpage>487</lpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Batlle</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Wilkinson</surname>, <given-names>D.G.</given-names></string-name> (<year>2012</year>). <article-title>Molecular mechanisms of cell segregation and boundary formation in development and tumorigenesis</article-title>. <source>Cold Spring Harb. Perspect. Biol</source>. <volume>4</volume>, <fpage>a008227</fpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Boyd</surname>, <given-names>A.W.</given-names></string-name>, <string-name><surname>Bartlett</surname>, <given-names>P.F.</given-names></string-name>, and <string-name><surname>Lackmann</surname>, <given-names>M.</given-names></string-name> (<year>2014</year>). <article-title>Therapeutic targeting of EPH receptors and their ligands</article-title>. <source>Nat. Rev. Drug Discov</source>. <volume>13</volume>, <fpage>39</fpage>&#x2013;<lpage>62</lpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhuang,G., Frieden</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Debinski</surname>, <given-names>W</given-names></string-name>. (<year>2008</year>). <article-title>Eph receptors and Ephrins in cancer: common themes and controversies</article-title>. <source>Cancer Res</source>. <volume>68</volume>, <fpage>10031</fpage>&#x2013;<lpage>10033</lpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>V.B.</given-names></string-name>, <string-name><surname>Arendall</surname>, <given-names>W.B.</given-names></string-name>, <string-name><surname>Headd</surname>, <given-names>J.J.</given-names></string-name>, <string-name><surname>Keedy</surname>, <given-names>D.A.</given-names></string-name>, <string-name><surname>Immormino</surname>, <given-names>R.M.</given-names></string-name>, <string-name><surname>Kapral</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Murray</surname>, <given-names>L.W.</given-names></string-name>, <string-name><surname>Richardson</surname>, <given-names>J.S.</given-names></string-name>, and <string-name><surname>Richardson</surname>, <given-names>D.C.</given-names></string-name> (<year>2010</year>). <article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title>. <source>Acta Crystallogr. D Biol. Crystallogr</source>. <volume>66</volume>, <fpage>12</fpage>&#x2013;<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Committee</surname>, <given-names>E.N.</given-names></string-name> (<year>1997</year>). <article-title>Unified Nomenclature for Eph Family Receptors and Their Ligands, the Ephrins</article-title>. <source>Cell</source> <volume>90</volume>, <fpage>403</fpage>&#x2013;<lpage>404</lpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Cooper</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Son</surname>, <given-names>A.I.</given-names></string-name>, <string-name><surname>Komlos</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Kleiman</surname>, <given-names>N.J.</given-names></string-name>, and <string-name><surname>Zhou</surname>, <given-names>R.</given-names></string-name> (<year>2008</year>). <article-title>Loss of ephrin-A5 function disrupts lens fiber cell packing and leads to cataract</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>. <volume>105</volume>, <fpage>16620</fpage>&#x2013;<lpage>16625</lpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Emsley</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Lohkamp</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Scott</surname>, <given-names>W.G.</given-names></string-name>, and <string-name><surname>Cowtan</surname>, <given-names>K.</given-names></string-name> (<year>2010</year>). <article-title>Features and development of Coot. Acta Crystallogr</article-title>. <source>D Biol. Crystallogr</source>. <volume>66</volume>, <fpage>486</fpage>&#x2013;<lpage>501</lpage>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Forbes</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Beare</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Boutselakis</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Bamford</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bindal</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Tate</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cole</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Ward</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Dawson</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Ponting</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Stefancsik</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Harsha</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Kok</surname>, <given-names>C.Y.</given-names></string-name>, <string-name><surname>Jia</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Jubb</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Sondka</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Thompson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>De</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Campbell</surname>, <given-names>PJ</given-names></string-name>. (<year>2017</year>). <article-title>COSMIC: somatic cancer genetics at high- resolution</article-title>. <source>Nucleic Acids Res</source>. <volume>45</volume>, <fpage>D777</fpage>&#x2013;<lpage>D783</lpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="book"><string-name><surname>Gaitanos</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Dudanova</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Sakkou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Paix&#x00E2;o</surname>, <given-names>S.</given-names></string-name> (<year>2015</year>). <chapter-title>The Eph Receptor Family. In Receptor Tyrosine Kinases: Family and Subfamilies</chapter-title>, <person-group person-group-type="editor"><string-name><given-names>D.L.</given-names> <surname>Wheeler</surname></string-name>, and <string-name><given-names>Y.</given-names> <surname>Yarden</surname></string-name>, eds</person-group>. (Cham: <publisher-name>Springer International Publishing</publisher-name>), pp. <fpage>165</fpage>&#x2013;<lpage>264</lpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Gale</surname>, <given-names>N.W.</given-names></string-name>, <string-name><surname>Holland</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Valenzuela</surname>, <given-names>D.M.</given-names></string-name>, <string-name><surname>Flenniken</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pan</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ryan</surname>, <given-names>T.E.</given-names></string-name>, <string-name><surname>Henkemeyer</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Strebhardt</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hirai</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Wilkinson</surname>, <given-names>D.G.</given-names></string-name>, <string-name><surname>Pawson</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>S.</given-names></string-name>, and <string-name><surname>Yancopoulos</surname>, <given-names>G.D.</given-names></string-name> (<year>1996</year>). <article-title>Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis</article-title>. <source>Neuron</source> <volume>17</volume>, <fpage>9</fpage>&#x2013;<lpage>19</lpage>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Genander</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Frisen</surname>, <given-names>J.</given-names></string-name> (<year>2010</year>). <article-title>Ephrins and Eph receptors in stem cells and cancer</article-title>. <source>Curr. Opin. Cell Biol</source>. <volume>22</volume>, <fpage>611</fpage>&#x2013;<lpage>616</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>Hahn</surname>, <given-names>A.S.</given-names></string-name>, <string-name><surname>Kaufmann</surname>, <given-names>J.K.</given-names></string-name>, <string-name><surname>Wies</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Naschberger</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Panteleev-Ivlev</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Schmidt</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Holzer</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Schmidt</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Konig</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ensser</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Myoung</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Brockmeyer</surname>, <given-names>N.H.</given-names></string-name>, <string-name><surname>Sturzl</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fleckenstein</surname>, <given-names>B.</given-names></string-name>, and <string-name><surname>Neipel</surname>, <given-names>F.</given-names></string-name> (<year>2012</year>). <article-title>The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi&#x2019;s sarcoma-associated herpesvirus</article-title>. <source>Nat. Med</source>. <volume>18</volume>, <fpage>961</fpage>&#x2013;<lpage>966</lpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal"><string-name><surname>Harada</surname>, <given-names>B.T.</given-names></string-name>, <string-name><surname>Knight</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Imai</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Qiao</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Ramachander</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Sawaya</surname>, <given-names>M.R.</given-names></string-name>, <string-name><surname>Gingery</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sakane</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>Bowie</surname>, <given-names>J.U.</given-names></string-name> (<year>2008</year>). <article-title>Regulation of enzyme localization by polymerization: polymer formation by the SAM domain of diacylglycerol kinase delta1</article-title>. <source>Structure</source> <volume>16</volume>, <fpage>380</fpage>&#x2013;<lpage>387</lpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Hirai</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Maru</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hagiwara</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Nishida</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Takaku</surname>, <given-names>F.</given-names></string-name> (<year>1987</year>). <article-title>A novel putative tyrosine kinase receptor encoded by the eph gene</article-title>. <source>Science</source> <volume>238</volume>, <fpage>1717</fpage>&#x2013;<lpage>1720</lpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Julich</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Mould</surname>, <given-names>A.P.</given-names></string-name>, <string-name><surname>Koper</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Holley</surname>, <given-names>S.A.</given-names></string-name> (<year>2009</year>). <article-title>Control of extracellular matrix assembly along tissue boundaries via Integrin and Eph/Ephrin signaling</article-title>. <source>Development</source> <volume>136</volume>, <fpage>2913</fpage>&#x2013;<lpage>2921</lpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>Kania</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Klein</surname>, <given-names>R.</given-names></string-name> (<year>2016</year>). <article-title>Mechanisms of ephrin-Eph signalling in development, physiology and disease</article-title>. <source>Nat. Rev. Mol. Cell Biol</source>. <volume>17</volume>, <fpage>240</fpage>&#x2013;<lpage>256</lpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Kim</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yoo</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Park</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Park</surname>, <given-names>S.</given-names></string-name> (<year>2010</year>). <article-title>The SAM domains of Anks family proteins are critically involved in modulating the degradation of EphA receptors</article-title>. <source>Mol. Cell. Biol</source>. <volume>30</volume>, <fpage>1582</fpage>&#x2013;<lpage>1592</lpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Knight</surname>, <given-names>M.J.</given-names></string-name>, <string-name><surname>Leettola</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Gingery</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>H.</given-names></string-name>, and <string-name><surname>Bowie</surname>, <given-names>J.U.</given-names></string-name> (<year>2011</year>). <article-title>A human sterile alpha motif domain polymerizome</article-title>. <source>Protein Sci</source>. <volume>20</volume>, <fpage>1697</fpage>&#x2013;<lpage>1706</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Lee</surname>, <given-names>H.J.</given-names></string-name>, <string-name><surname>Hota</surname>, <given-names>P.K.</given-names></string-name>, <string-name><surname>Chugha</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Guo</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Miao</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Stetzik</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>A. C.</given-names></string-name>, and <string-name><surname>Buck</surname>, <given-names>M.</given-names></string-name> (<year>2012</year>). <article-title>NMR structure of a heterodimeric SAM:SAM complex: characterization and manipulation of EphA2 binding reveal new cellular functions of SHIP2</article-title>. <source>Structure</source> <volume>20</volume>, <fpage>41</fpage>&#x2013;<lpage>55</lpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Lemmon</surname>, <given-names>M.A.</given-names></string-name>, and <string-name><surname>Schlessinger</surname>, <given-names>J.</given-names></string-name> (<year>2010</year>). <article-title>Cell signaling by receptor tyrosine kinases</article-title>. <source>Cell</source> <volume>141</volume>, <fpage>1117</fpage>&#x2013;<lpage>1134</lpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Leone</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cellitti</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Pellecchia</surname>, <given-names>M.</given-names></string-name> (<year>2009</year>). <article-title>The Sam domain of the lipid phosphatase Ship2 adopts a common model to interact with Arap3-Sam and EphA2-Sam</article-title>. <source>BMC Struct. Biol</source>. <volume>9</volume>, <fpage>59</fpage>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Wen</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Ye</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>C.H.</given-names></string-name>, <string-name><surname>Hardie</surname>, <given-names>R.</given-names></string-name>, and <string-name><surname>Zhang</surname>, <given-names>M.</given-names></string-name> (<year>2011</year>). <article-title>The INAD Scaffold Is a Dynamic, Redox-Regulated Modulator of Signaling in the Drosophila Eye</article-title>. <source>Cell</source> <volume>145</volume>, <fpage>1088</fpage>&#x2013;<lpage>1101</lpage>.</mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Lo</surname>, <given-names>P.H.</given-names></string-name>, <string-name><surname>Tanikawa</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Katagiri</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Nakamura</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>Matsuda</surname>, <given-names>K.</given-names></string-name> (<year>2015</year>). <article-title>Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma</article-title>. <source>Oncol. Rep</source>. <volume>33</volume>, <fpage>267</fpage>&#x2013;<lpage>273</lpage>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Ma</surname>, <given-names>J.C.</given-names></string-name>, and <string-name><surname>Dougherty</surname>, <given-names>D.A.</given-names></string-name> (<year>1997</year>). <article-title>The Cation-&#x03C0; Interaction</article-title>. <source>Chem. Rev</source>. <volume>97</volume>, <fpage>1303</fpage>&#x2013;<lpage>1324</lpage>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Manning</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Plowman</surname>, <given-names>G.D.</given-names></string-name>, <string-name><surname>Hunter</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Sudarsanam</surname>, <given-names>S.</given-names></string-name> (<year>2002</year>). <article-title>Evolution of protein kinase signaling from yeast to man</article-title>. <source>Trends Biochem. Sci</source>. <volume>27</volume>, <fpage>514</fpage>&#x2013;<lpage>520</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Mccoy</surname>, <given-names>A.J.</given-names></string-name>, <string-name><surname>Grosse-Kunstleve</surname>, <given-names>R.W.</given-names></string-name>, <string-name><surname>Adams</surname>, <given-names>P.D.</given-names></string-name>, <string-name><surname>Winn</surname>, <given-names>M.D.</given-names></string-name>, <string-name><surname>Storoni</surname>, <given-names>L.C.</given-names></string-name>, and <string-name><surname>Read</surname>, <given-names>R.J.</given-names></string-name> (<year>2007</year>). <article-title>Phaser crystallographic software</article-title>. <source>J. Appl. Crystallogr</source>. <volume>40</volume>, <fpage>658</fpage>&#x2013;<lpage>674</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>McMillen</surname>, <given-names>P.</given-names></string-name>, and <string-name><surname>Holley</surname>, <given-names>S.A.</given-names></string-name> (<year>2015</year>). <article-title>Integration of cell-cell and cell-ECM adhesion in vertebrate morphogenesis</article-title>. <source>Curr. Opin. Cell Biol</source>. <volume>36</volume>, <fpage>48</fpage>&#x2013;<lpage>53</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Mercurio</surname>, <given-names>F.A.</given-names></string-name>, <string-name><surname>Marasco</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Pirone</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Pedone</surname>, <given-names>E.M.</given-names></string-name>, <string-name><surname>Pellecchia</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Leone</surname>, <given-names>M.</given-names></string-name> (<year>2012</year>). <article-title>Solution structure of the first Sam domain of Odin and binding studies with the EphA2 receptor</article-title>. <source>Biochemistry</source> <volume>51</volume>, <fpage>2136</fpage>&#x2013;<lpage>2145</lpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Merlos-Suarez</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Batlle</surname>, <given-names>E.</given-names></string-name> (<year>2008</year>). <article-title>Eph-ephrin signalling in adult tissues and cancer</article-title>. <source>Curr. Opin. Cell Biol</source>. <volume>20</volume>, <fpage>194</fpage>&#x2013;<lpage>200</lpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Miao</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Burnett</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Kinch</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Simon</surname>, <given-names>E.</given-names></string-name>, and <string-name><surname>Wang</surname>, <given-names>B.</given-names></string-name> (<year>2000</year>). <article-title>Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation</article-title>. <source>Nat. Cell Biol</source>. <volume>2</volume>, <fpage>62</fpage>&#x2013;<lpage>69</lpage>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Munarini</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>J&#x00E0;ger</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Abderhalden</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zuercher</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Rohrbach</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Loercher</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Pfanner-Meyer</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Andres</surname>, <given-names>A.C.</given-names></string-name>, <string-name><surname>Ziemiecki</surname>, <given-names>A.</given-names></string-name> (<year>2002</year>). <article-title>Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase</article-title>. <source>J. Cell Sci</source>. <volume>115</volume>, <fpage>25</fpage>&#x2013;<lpage>37</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Murai</surname>, <given-names>K.K.</given-names></string-name>, and <string-name><surname>Pasquale</surname>, <given-names>E.B.</given-names></string-name> (<year>2003</year>). <article-title>Eph&#x2019;ective signaling: forward, reverse and crosstalk</article-title>. <source>J. Cell Sci</source>. <volume>116</volume>, <fpage>2823</fpage>&#x2013;<lpage>2832</lpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Murshudov</surname>, <given-names>G.N.</given-names></string-name>, <string-name><surname>Skubak</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Lebedev</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Pannu</surname>, <given-names>N.S.</given-names></string-name>, <string-name><surname>Steiner</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Nicholls</surname>, <given-names>R.A.</given-names></string-name>, <string-name><surname>Winn</surname>, <given-names>M.D.</given-names></string-name>, <string-name><surname>Long</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>Vagin</surname>, <given-names>A.A.</given-names></string-name> (<year>2011</year>). <article-title>REFMAC5 for the refinement of macromolecular crystal structures</article-title>. <source>Acta Crystallogr. D Biol. Crystallogr</source>. <volume>67</volume>, <fpage>355</fpage>&#x2013;<lpage>367</lpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><string-name><surname>Otwinowski</surname>, <given-names>Z.</given-names></string-name>, and <string-name><surname>Minor</surname>, <given-names>W.</given-names></string-name> (<year>1997</year>). <article-title>Processing of X-ray diffraction data collected in oscillation mode</article-title>. <source>Methods Enzymol</source>. <volume>276</volume>, <fpage>307</fpage>&#x2013;<lpage>326</lpage>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Park</surname>, <given-names>E.C.</given-names></string-name>, <string-name><surname>Cho</surname>, <given-names>G.S.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>G.H.</given-names></string-name>, <string-name><surname>Choi</surname>, <given-names>S.C.</given-names></string-name>, and <string-name><surname>Han</surname>, <given-names>J.K.</given-names></string-name> (<year>2011</year>). <article-title>The involvement of Eph- Ephrin signaling in tissue separation and convergence during Xenopus gastrulation movements</article-title>. <source>Dev. Biol</source>. <volume>350</volume>, <fpage>441</fpage>&#x2013;<lpage>450</lpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Pasquale</surname>, <given-names>E.B.</given-names></string-name> (<year>2005</year>). <article-title>Eph receptor signalling casts a wide net on cell behaviour</article-title>. <source>Nat. Rev. Pasquale, E.B</source>. (2008). Eph-ephrin bidirectional signaling in physiology and disease. Cell <volume>133</volume>, <fpage>38</fpage>&#x2013;<lpage>52</lpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><string-name><surname>Pasquale</surname>, <given-names>E.B.</given-names></string-name> (<year>2010</year>). <article-title>Eph receptors and ephrins in cancer: bidirectional signalling and beyond</article-title>. <source>Nat. Rev. Cancer</source> <volume>10</volume>, <fpage>165</fpage>&#x2013;<lpage>180</lpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Pitulescu</surname>, <given-names>M.E.</given-names></string-name>, and <string-name><surname>Adams</surname>, <given-names>R.H.</given-names></string-name> (<year>2010</year>). <article-title>Eph/ephrin molecules&#x2013;a hub for signaling and endocytosis</article-title>. <source>Genes Dev</source>. <volume>24</volume>, <fpage>2480</fpage>&#x2013;<lpage>2492</lpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Poliakov</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Cotrina</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Wilkinson</surname>, <given-names>D.G.</given-names></string-name> (<year>2004</year>). <article-title>Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly</article-title>. <source>Dev. Cell</source> <volume>7</volume>, <fpage>465</fpage>&#x2013;<lpage>480</lpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="other"><string-name><surname>Qiao</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>Bowie</surname>, <given-names>J.U.</given-names></string-name> (<year>2005</year>). <article-title>The many faces of SAM</article-title>. <source>Sci. STKE 2005</source>, <fpage>re7</fpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><string-name><surname>Shi</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Hapiak</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Muller-Greven</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bowman</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Lingerak</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Buck</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>B.C.</given-names></string-name>, and <string-name><surname>Smith</surname>, <given-names>A.W.</given-names></string-name> (<year>2017</year>). <article-title>A role of the SAM domain in EphA2 receptor activation</article-title>. <source>Sci. Rep</source>. <volume>7</volume>, <fpage>45084</fpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><string-name><surname>Stapleton</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Balan</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Pawson</surname>, <given-names>T.</given-names></string-name>, and <string-name><surname>Sicheri</surname>, <given-names>F.</given-names></string-name> (<year>1999</year>). <article-title>The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization</article-title>. <source>Nat. Struct. Biol</source>. <volume>6</volume>, <fpage>44</fpage>&#x2013;<lpage>49</lpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><string-name><surname>Taylor</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Campbell</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Nobes</surname>, <given-names>C.D.</given-names></string-name> (<year>2017</year>). <article-title>Ephs and ephrins</article-title>. <source>Curr. Biol</source>. <volume>27</volume>, <fpage>R90</fpage>&#x2013;<lpage>R95</lpage>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><string-name><surname>Thanos</surname>, <given-names>C.D.</given-names></string-name>, <string-name><surname>Goodwill</surname>, <given-names>K.E.</given-names></string-name>, and <string-name><surname>Bowie</surname>, <given-names>J.U.</given-names></string-name> (<year>1999</year>). <article-title>Oligomeric Structure of the Human EphB2 Receptor SAM Domain</article-title>. <source>Science</source> <volume>283</volume>, <fpage>833</fpage>&#x2013;<lpage>836</lpage>.</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>G.</given-names></string-name>, and <string-name><surname>Liu</surname>, <given-names>W.</given-names></string-name> (<year>2016</year>). <article-title>Systematic biochemical characterization of the SAM domains in Eph receptor family from Mus Musculus</article-title>. <source>Biochem. Biophys. Res. Commun</source>. <volume>473</volume>, <fpage>1281</fpage>&#x2013;<lpage>1287</lpage>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><string-name><surname>Ye</surname>, <given-names>F.</given-names></string-name>, and <string-name><surname>Zhang</surname>, <given-names>M.</given-names></string-name> (<year>2013</year>). <article-title>Structures and target recognition modes of PDZ domains: recurring themes and emerging pictures</article-title>. <source>Biochem. J</source>. <volume>455</volume>, <fpage>1</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><string-name><surname>Yokoyama</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Romero</surname>, <given-names>M.I.</given-names></string-name>, <string-name><surname>Cowan</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Galvan</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Helmbacher</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Charnay</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Parada</surname>, <given-names>L.F.</given-names></string-name>, <string-name><surname>Henkemeyer</surname>, <given-names>M.</given-names></string-name> (<year>2001</year>). <article-title>Forward Signaling Mediated by Ephrin-B3 Prevents Contralateral Corticospinal Axons from Recrossing the Spinal Cord Midline</article-title>. <source>Neuron</source> <volume>29</volume>, <fpage>85</fpage>&#x2013;<lpage>97</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Martinez</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Haber</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Jones</surname>, <given-names>E.V.</given-names></string-name>, <string-name><surname>Bouvier</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Doucet</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Corera</surname>, <given-names>A.T.</given-names></string-name>, <string-name><surname>Fon</surname>, <given-names>E.A.</given-names></string-name>, <string-name><surname>Zisch</surname>, <given-names>A.H.</given-names></string-name>, and <string-name><surname>Murai</surname>, <given-names>K.K.</given-names></string-name> (<year>2007</year>). <article-title>EphA4 signaling regulates phospholipase Cgamma1 activation, cofilin membrane association, and dendritic spine morphology</article-title>. <source>J. Neurosci</source>. <volume>27</volume>, <fpage>5127</fpage>&#x2013;<lpage>5138</lpage>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><string-name><surname>Zhuang</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Hunter</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Hwang</surname>, <given-names>Y.</given-names></string-name>, and <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name> (<year>2007</year>). <article-title>Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation</article-title>. <source>J. Biol. Chem</source>. <volume>282</volume>, <fpage>2683</fpage>&#x2013;<lpage>2694</lpage>.</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><string-name><surname>Zhuang</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Song</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Amato</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hwang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Boothby</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ye</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Guo</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Shyr</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Carbone</surname>, <given-names>D.P.</given-names></string-name>, <string-name><surname>Brantley-Sieders</surname>, <given-names>D.M.</given-names></string-name>, and <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name> (<year>2012</year>). <article-title>Effects of cancer- associated EPHA3 mutations on lung cancer</article-title>. <source>J. Natl. Cancer Inst</source>. <volume>104</volume>, <fpage>1182</fpage>&#x2013;<lpage>1197</lpage>.</mixed-citation></ref>
</ref-list>
<sec id="s5" sec-type="supplymentary-material">
<title>Supplementary Figures</title>
<fig id="figS1" position="float" orientation="portrait" fig-type="figure">
<label>Figure S1.</label>
<caption><title>The structures of the EphA2-SHIP2 and EphA6-Odin SAM-SAM complexes showing the linkers used to connect the SAM domains in both structure are sufficiently long and flexible.</title><p>Ribbon diagram of the SHIP2 SAM-EphA2 SAM (<italic>left</italic>) and Odin SAM1-EphA6 SAM (<italic>right</italic>) structures. The 14-residue fusion linker is not defined in the electron density map in the SHIP2 SAM-EphA2 SAM structure and shown as the dashed line. The 17-residue fusion linker is well defined and stabilized by crystal packing in the Odin SAM1-EphA6 SAM structure. The grey dotted lines show the distances between the C-terminus of SHIP2 SAM or Odin SAM1 and the corresponding Eph SAM N-terminus is &#x007E;23 &#x00C2; and &#x007E;20 &#x00C2;, respectively.</p></caption>
<graphic xlink:href="263137_figS1.tif"/>
</fig>
<fig id="figS2" position="float" orientation="portrait" fig-type="figure">
<label>Figure S2.</label>
<caption><title>The key Arg958<sup>A2</sup>/Phe1226<sup>SHIP2</sup> cation-&#x03C0; interaction was not resolved in the previous NMR study.</title><p>(A) Overall structure of an earlier NMR-derived EphA2 SAM/SHIP2 SAM heterodimer shown at the same view as our crystal structure in <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</p>
<p>(B) The Arg958<sup>A2</sup>/Phe1226<sup>SHIP2</sup> cation-&#x03C0; interaction revealed in our study was not defined in the NMR experiments as shown by four representative structures from the ensemble deposited.</p></caption>
<graphic xlink:href="263137_figS2.tif"/>
</fig>
<fig id="figS3" position="float" orientation="portrait" fig-type="figure">
<label>Figure S3.</label>
<caption><title>Neither EphA2 nor SHIP2 SAM can form homo-oligomers or polymerize into hetero-oligomers.</title><p>Open-book views of the surfaces of the EphA2/SHIP2 SAM-SAM interfaces showing the charge complementation. The corresponding End-Helix surface of SHIP2 is not positively charged compared with the End-Helix surface of EphA2 SAM and the corresponding Mid-Loop surface of EphA2 is not negatively charged compared with the Mid-Loop surface of SHIP2 SAM. The surface electrostatic potentials were calculated by APBS and contoured at 3.5 kBT/eC.</p></caption>
<graphic xlink:href="263137_figS3.tif"/>
</fig>
<fig id="figS4" position="float" orientation="portrait" fig-type="figure">
<label>Figure S4.</label>
<caption><title>The critical role of Gly at the beginning of &#x03B1;5 from Eph SAM in SAM/SAM interactions.</title><p>The backbone methylene of a Gly residue at the beginning of &#x03B1;5 from Eph SAM (Gly954<sup>A2</sup>/Gly1104<sup>A6</sup>) is in close contact with an aromatic residue from SHIP2/Odin SAM (Trp1221<sup>SHIP2</sup>/Phe738<sup>Odin</sup>) (A&#x0026;B). In EphA5/SAMD5 complex, Gly853 is in close contact with G27<sup>SAMD5</sup> backbone and V32<sup>SAMD5</sup> sidechain (C). The black dashed lines indicate the distances between two atoms are within 4 &#x00C2;.</p></caption>
<graphic xlink:href="263137_figS4.tif"/>
</fig>
<fig id="figS5" position="float" orientation="portrait" fig-type="figure">
<label>Figure S5.</label>
<caption><title>Sequence alignments of Eph SAM domains among different family members or across species.</title><p>Sequence alignments of all human Eph SAM domains (A) and members of EphA2 (B), EphA6 (C) and EphA5 (D) from 4-5 representative vertebrate species. The secondary structure elements are labeled according to the EphA2 SAM structure. Residues that are identical and highly similar are indicated in red and yellow boxes, respectively. The critical residues for Eph SAM interaction specificity described in the manuscript are indicated with blue arrows.</p></caption>
<graphic xlink:href="263137_figS5.tif"/>
</fig>
</sec>
</back>
</article>
